ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States.

Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations.

The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms.

It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc.

The company was incorporated in 2014 and is headquartered in South San Francisco, California.